Two questions raised by yesterday's Novartis-Alcon [1] announcement. Is the Swiss drug maker in the market for more deals? And might Novartis offload its one-third stake in Roche to pay for Alcon or some other acquisition. CEO Daniel Vasella (photo [2]) answers both: No. Report [3] | Report [4]
Links:
[1] http://www.fiercepharma.com/story/novartis-pledges-39b-for-alcon/2008-04-07
[2] http://www.fiercebiotech.com/pages/novartis-ceo-daniel-vasella
[3] http://www.iii.co.uk/news/?type=afxnews&articleid=6644749&subject=companies&action=article
[4] http://www.forbes.com/markets/feeds/afx/2008/04/07/afx4861145.html